Pneumococcal Vaccine is a subunit vaccine commercialized by CanSino Biologics, with a leading Phase I program in Streptococcal Pneumonia. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Pneumococcal Vaccine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Pneumococcal Vaccine is expected to reach an annual total of $1 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pneumococcal Vaccine Overview
Protein-based pneumococcal vaccine is under development for the prevention of streptococcal pneumonia infections. The therapeutic candidate is a serotype-independent protein-based pneumococcal vaccine. It is administered through intramuscular route.
CanSino Biologics Overview
CanSino Biologics. (CanSinoBIO) is a biopharmaceutical company carries out research, development, manufacturing, and commercialization of vaccine products for human use. The company offers pipeline products such as the COVID-19 vaccine (adenovirus type 5 vector) for inhalation, group ACYW135 meningococcal conjugate vaccine (CRM197 vector), Ad5-EBOV, PCV13i (CRM197/TT double vector), DTcP infant, absorbed tetanus vaccine, COVID-19 mRNA vaccine and others. Its products are developed using platform technologies including Adenovirus-based viral vector technology, Synthetic biotechnology, Protein structure design and VLP assembly, mRNA and LNP technology, and Formulation and drug delivery technology. CanSinoBIO distributes its products through a marketing and supply system in China, Southeast Asia, the Middle East, Latin America, and other regions. The company operates manufacturing offices in Mexico, China, Pakistan, and Malaysia. CanSino Biologics is headquartered in Tianjin, China.
The company reported revenues of (Renminbi) CNY345.2 million for the fiscal year ended December 2023 (FY2023), a decrease of 66.5% over FY2022. The operating loss of the company was CNY2,035.2 million in FY2023, compared to an operating loss of CNY1,368.7 million in FY2022. The net loss of the company was CNY1,482.7 million in FY2023, compared to a net loss of CNY909.4 million in FY2022.
For a complete picture of Pneumococcal Vaccine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
